Pemetrexed Alimta for Advanced Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) - Details


( Last Updated : December 5, 2013)
Generic Name:
Pemetrexed
Project Status:
Complete
Therapeutic Area:
Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Manufacturer:
Eli Lilly Canada
Brand Name:
Alimta
Project Line:
Reimbursement Review
Project Number:
PC0027-000
NOC Date:

Details


Strength:
100mg/vial and 500mg/vial
Tumour Type:
Lung
Indications:
Advanced Non-Squamous Non Small Cell Lung Cancer
Funding Request:
For maintenance following first-line pemetrexed and cisplatin for advanced or metastatic Non Squamous -Non Small Cell Lung Cancer (NS-NSCLC)
Review Status:
Complete
Sponsor:
Eli Lilly Canada
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.